Obseva SA (NASDAQ:OBSV) – Stock analysts at Wedbush decreased their FY2021 earnings estimates for shares of Obseva in a research report issued to clients and investors on Wednesday, November 28th. Wedbush analyst L. Moussatos now expects that the company will post earnings per share of ($2.90) for the year, down from their prior estimate of ($2.84). Wedbush has a “Buy” rating and a $34.00 price target on the stock. Wedbush also issued estimates for Obseva’s FY2022 earnings at ($2.08) EPS.
Several other equities analysts also recently weighed in on the company. Zacks Investment Research upgraded Obseva from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, October 18th. HC Wainwright set a $44.00 target price on Obseva and gave the company a “buy” rating in a research report on Monday, October 15th. TheStreet upgraded Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. JPMorgan Chase & Co. assumed coverage on Obseva in a research report on Thursday, September 13th. They set an “overweight” rating and a $29.00 target price on the stock. Finally, Leerink Swann assumed coverage on Obseva in a research report on Wednesday, August 15th. They set an “outperform” rating and a $25.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $29.43.
Obseva (NASDAQ:OBSV) last released its earnings results on Thursday, November 8th. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.04.
Institutional investors have recently made changes to their positions in the company. United Services Automobile Association purchased a new position in shares of Obseva in the third quarter valued at about $206,000. US Bancorp DE purchased a new position in shares of Obseva in the second quarter valued at about $197,000. Tiverton Asset Management LLC purchased a new position in shares of Obseva in the second quarter valued at about $224,000. Dimensional Fund Advisors LP purchased a new position in shares of Obseva in the third quarter valued at about $340,000. Finally, Jane Street Group LLC purchased a new position in shares of Obseva in the second quarter valued at about $349,000. Institutional investors and hedge funds own 72.19% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: Swap
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.